Patents
Literature
2 results about "Midkine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Midkine (MK or MDK) also known as neurite growth-promoting factor 2 (NEGF2) is a protein that in humans is encoded by the MDK gene. Midkine is a basic heparin-binding growth factor of low molecular weight, and forms a family with pleiotrophin (NEGF1, 46% homologous with MK). It is a nonglycosylated protein, composed of two domains held by disulfide bridges. It is a developmentally important retinoic acid-responsive gene product strongly induced during mid-gestation, hence the name midkine. Restricted mainly to certain tissues in the normal adult, it is strongly induced during oncogenesis, inflammation and tissue repair.
Methods for treating developmental dysplasis of hip
ActiveUS12636277B2Organic active ingredientsSkeletal disorderPharmaceutical drugPharmaceutical Substances
Embodiments of the present disclosure provide a method for treating developmental dysplasia of the hip. The method includes administering a therapeutically effective amount of a pharmaceutical composition to a subject suffering from the developmental dysplasia of the hip. The pharmaceutical composition includes a substance capable of inhibiting expression of Midkine (MDK), and the substance capable of inhibiting the expression of MDK is Midkine inhibitor (IMDK).
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Orally Active, Brain Penetrant First-in-Class Small Molecule Midkine (MDK) Inhibitors for the Treatment of Malignancies and Non-Malignant Diseases
An orally active, brain penetrant first-in-class small molecule midkine inhibitor for use in the treatment of triple-negative breast cancer, brain tumors (including glioblastoma, medulloblastoma, and NF1-mutant optic pathway gliomas), ovarian and endometrial cancers, lung cancer, as well as gynecologic non-malignant conditions such as endometriosis, uterine fibroids, and preterm birth, in which tumor cells and / or pathological cells exhibit heightened midkine signaling and express multiple midkine receptors.
